How far will the Voyager ® take us?

There are several reasons for this, which relate to drug delivery to infiltrative tumor cells behind the blood-brain barrier (BBB), drug residence time on tumor cell target, appropriateness of cellular target and the need to inhibit more than one cellular target, drug pharmacokinetics and drug safet...

Full description

Saved in:
Bibliographic Details
Published in:CNS oncology 2019-03, Vol.8 (1)
Main Author: Levin, Victor A
Format: Article
Language:English
Subjects:
Brain cancer
Cancer therapies
Chemotherapy
Drugs
electromagnetic fields
FDA approval
Feasibility studies
Gene expression
glioblastoma
Immunotherapy
Magnetic fields
Medical equipment
Medical technology
Oncology
paclitaxel mimic
Patients
PD-1 inhibitor
Radiation therapy
Radio frequency
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There are several reasons for this, which relate to drug delivery to infiltrative tumor cells behind the blood-brain barrier (BBB), drug residence time on tumor cell target, appropriateness of cellular target and the need to inhibit more than one cellular target, drug pharmacokinetics and drug safety (8,9). The Voyager potential for new GBM therapies In this issue, the first clinical reports are published for the Nativis Voyager®, an investigational therapeutic medical device under development for the treatment of brain cancer in adults and children that exerts its action by mimicking drug effects on tumor targets (10,11). The Voyager utilizes proprietary ultra-low radio frequency energy (ulRFE® ) technology to produce a cognate reflecting the binding of a molecule (e.g.,chemotherapy drug or siRNA) to a cellular target by measuring and recording the subtle oscillating magnetic field produced by molecules in solution using a superconducting quantum interference device (SQUID). Financial and competing interests disclosure The author is the Founder and Senior Medical Adviser for Orbus Therapeutics,DMC Chair for Bristol-Myers Squibb clinical trials and a member of SAB for Nativis, Inc. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
ISSN:2045-0907
2045-0915
DOI:10.2217/cns-2018-0019